Impact of Newborn Screening on Survival and Developmental Outcome in Classic Isovaleric Aciduria: A Meta‐Analysis
Journal of Inherited Metabolic Disease · 2025
DOI: 10.1002/jimd.70090 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Journal of Inherited Metabolic Disease, 2025. Verfasst von Anna T Reischl-Hajiabadi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty of Heidelberg, Department of Pediatrics I, Division of Pediatric Neurology and Metabolic Medicine, Heidelberg University, Heidelberg,…. Hauptthemen laut MEDLINE: Neonatal Screening, Amino Acid Metabolism, Inborn Errors, Isovaleryl-CoA Dehydrogenase. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dietmar Hopp Stiftung.
Abstract (Originalsprache)
Classic isovaleric aciduria (cIVA) is a rare inherited metabolic disorder characterized by recurrent life‐threatening metabolic decompensations and neurocognitive impairment in untreated patients. This meta‐analysis aims to assess the impact of early diagnosis by newborn screening (NBS) on mortality and neurocognitive outcome. A systematic literature search for articles published until 2022 was conducted following PRISMA protocol guidelines. We investigated effects on clinical outcomes and survival, analyzing outcome parameters using meta‐analytical measures and estimating effect sizes with a random‐effects model. Overall, 20 studies were included, reporting on 240 individuals with cIVA. Individuals identified by NBS presented with a lower frequency of neurological symptoms (13.0% vs. 44.9%; p = 0.0040) and developmental delay (6.1% vs. 51.2%; p < 0.0001), and had a lower mortality rate (1.1% vs. 10.9%; p = 0.0320). The quality of healthcare systems did not have a measurable impact on neurocognitive outcome and mortality. Despite the beneficial effect of NBS on clinical outcome and mortality, it could not reliably prevent the manifestation of neonatal decompensation in all individuals with cIVA identified by NBS. Early diagnosis through NBS is essential for the timely initiation of therapy and for improving outcomes and survival rates in individuals with cIVA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Faculty of Heidelberg, Department of Pediatrics I, Division of Pediatric Neurology and Metabolic Medicine, Heidelberg University, Heidelberg, Germany.
ORCID-Profile: Anna T Reischl-Hajiabadi, Sven F Garbade, Elena Schnabel-Besson, Roland Posset
Förderung
- Dietmar Hopp Stiftung
Zitieren
APA
Reischl-Hajiabadi, A. T., Garbade, S. F., Gleich, F., Schnabel-Besson, E., Posset, R., Zielonka, M., Hoffmann, G. F., Kölker, S., & Mütze, U. (2025). Impact of Newborn Screening on Survival and Developmental Outcome in Classic Isovaleric Aciduria: A Meta‐Analysis. Journal of Inherited Metabolic Disease. https://doi.org/10.1002/jimd.70090
Vancouver
Reischl-Hajiabadi AT, Garbade SF, Gleich F, Schnabel-Besson E, Posset R, Zielonka M, et al. Impact of Newborn Screening on Survival and Developmental Outcome in Classic Isovaleric Aciduria: A Meta‐Analysis. Journal of Inherited Metabolic Disease. 2025. doi:10.1002/jimd.70090
BibTeX
@article{ReischlHajiabadi2025,
author = {Reischl-Hajiabadi, Anna T and Garbade, Sven F and Gleich, Florian and Schnabel-Besson, Elena and Posset, Roland and Zielonka, Matthias and Hoffmann, Georg F and Kölker, Stefan and Mütze, Ulrike},
title = {Impact of Newborn Screening on Survival and Developmental Outcome in Classic Isovaleric Aciduria: A Meta‐Analysis},
journal = {Journal of Inherited Metabolic Disease},
year = {2025},
doi = {10.1002/jimd.70090}
}
EUVIMED